tbuckley/cabot-search huggingface dataset:
FRI0385 Non-Thrombotic Primary Antiphospholipid Kidney Disease, Longitudinal Follow up and Treatment Recomendations
Authors: L. Olguin, M. Alcala, C. Cruz
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Renal disease associated with antiphospholipid syndrome has been studied for many years and vascular thrombotic lesions have predominantly been described. However, an expanding spectrum of renal diseases associated with APS has also been encountered and although "non-thrombotic" nephropaties have been reported, they are infrequent and poorly characterized. <h3>Objectives</h3> To analyze the clinical and histological features of non-thrombotic kidney disease in a cohort of primary antiphospholipid syndrome (PAPS) patients and to propose treatment patterns besides anticoagulant therapy. <h3>Methods</h3> From a dynamic cohort of 60 PAPS patients we identified 20 patients with decreased creatinine clearance (&lt;60 ml/min) at least 2 times. All patients were receiving oral anticoagulation with a target INR 2-3, they underwent a renal function protocol which included: bimonthly creatinine clearance measurement, serum creatinine levels, urinalysis and arterial hypertension surveillance. If any of these parameters was abnormal, renal doppler, functional kidney scintigraphy and if possible, ultrasound-guided kidney biopsy was performed. After diagnosis of kidney disease, antihypertensives, mainly felodipine or enalapril were started regardless arterial hypertension. Patients have underwent follow-up for at least 12 months (range 14-136 months) <h3>Results</h3> 20 patients (33%) from our cohort were identified. Demographic characteristics were: 5 male and15 female, mean age ± 38.6 years, mean disease duration 9.6 years. 8 patients had diastolic pressure &gt;90 mmHg, the rest of them were normotensive. Median creatinine clearance was 46 ml/min ±8.3. Basal kidney scintigraphy reported diminished glomerular filtration rates in 16 patients. Renal Doppler was abnormal in 3 patients. Kidney biopsy was performed in 10 patients, histologic findings were: fibrous intimal thickening with luminal reduction in 9 cases, 18 patients had intimal hyperplasia, 18 biopsies reported mesangial hypercellularity, none of the renal specimens showed thrombosis or thrombotic mycroangiopathy. At follow up creatinine clearance raised to 79 ml/min ant month 4 and remains stable. <h3>Conclusions</h3> The spectrum of PAPS renal disease is expanding and in patients under anticoagulant therapy with optimum INR, a new class of kidney disease without thrombotic findings but with some degree of diminished renal function sensitive to vasodilator drugs seems to be quite prevalent. Therefore we advise to follow up renal function regularly and to start vasodilators such as calcium channel blockers and/or angiotensin inhibitors. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5982
TCT-501 Dual Antiplatelet Therapy Interruption For Surgery: Insights From The PARIS (Patterns Of Non-adherence To Anti-Platelet Regiments In Stented Patients) Registry
Authors: Mikkel Schoos, Aarti Bhasin, Samantha Sartori, Melissa Aquino, Jennifer Yu, Timothy D. Henry, David Cohen, David J. Moliterno, Cono Ariti, Roxana Mehran
Journal: Journal of the American College of Cardiology (2014)
NIH Assessors See Much To Improve on Campus
Authors: J. Randal
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article NIH Assessors See Much To Improve on Campus Get access Judy Randal Judy Randal Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 12, 15 June 1994, Pages 894–896, https://doi.org/10.1093/jnci/86.12.894 Published: 15 June 1994
AB0265 RADAI-5 remission represents 2011 ACR/EULAR proposal for remission with high specificity
Authors: B. Rintelen, J. Sautner, P.M. Haindl, H.T. Mai, H.-P. Brezinschek, B.F. Leeb
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> New remission criteria for Rheumatoid Arthritis (RA) were recently proposed by ACR and EULAR (1). It was of interest if a patient centred disease activity score as the Rheumatoid Arthritis Disease Activity Index based on 5 questions (RADAI-5) (2,3) meets these criteria. <h3>Objectives</h3> To approve RADAI-5 remission criteria with the recently proposed ACR/EULAR remission criteria for rheumatoid arthritis. <h3>Methods</h3> 729 RA outpatients were assessed according to the RADAI-5 as well as the two approaches of the recently published ACR/EULAR proposal (Boolean based and index based) being in remission or not. 1844 assessments (mean interval of the single assessments 6.7 months, mean number of assessments/pat 2.5) were included in this study. Sensitivity, specificity, positive and negative likelihood ratio (+LR, -LR) and ROC-analysis (area under the curve (AUC)) were performed to illustrate the relation of the 3 different approaches defining remission. <h3>Results</h3> Comparing the RADAI-5 remission group with Boolean based definition showed a sensitivity of 83%, specificity of 88%, +LR 6.7, -LR 0.19 and AUC 0.85: Comparison with index based definition showed 59%, 91%, 5.96, 0.46, 0.75 respectively. Core set parameters were significantly different comparing assessments of the RADAI-5 and Boolean- as well as index based remission group except patient's global assessment compared with the index based and ESR with the Boolean based definition group. <h3>Conclusions</h3> Although core set parameters are different, the RADAI-5 remission is comparable to ACR/EULAR remission criteria showing high specificity with the index based as well as Boolean based definition on group level. <h3>References</h3> Felson DT, Smolen JS, Wells G et al. Ann Rheum Dis. 2011 Mar;70(3):404-13; Leeb BF, Haindl PM, Maktari A et al. J Rheumatol. 2008 Jul;35(7):1294-9; Rintelen B, Haindl PM, Sautner J et al. J Rheumatol. 2009 May;36(5):918-24 <h3>Disclosure of Interest</h3> None Declared
Asbestos-Associated Diseases in a Cohort of Cigarette-Filter Workers
Authors: James A. Talcott, Wendy A. Thurber, Arlene F. Kantor, Edward A. Gaensler, Jane F. Danahy, Karen H. Antman, Frederick P. Li
Journal: New England Journal of Medicine (1989)

To estimate the effects on health of occupational exposure to crocidolite, a highly toxic form of asbestos, we studied a cohort of 33 men who worked in 1953 in a Massachusetts factory that manufactured cigarette filters containing crocidolite fibers from 1951 to 1957. Twenty-eight of the men have died, as compared with 8.3 deaths expected. This increased mortality was attributable to asbestos-associated diseases. Fifteen deaths were caused by cancer, as compared with 1.8 expected (relative risk, 8.2; 95 percent confidence interval, 4.6 to 13.4), including eight from lung cancer, five from malignant mesothelioma, and two from other types of cancer. There were seven deaths from nonmalignant respiratory disease, as compared with 0.5 expected (relative risk, 14.7; 95 percent confidence interval, 5.9 to 30.3), of which five were due primarily to asbestosis. In contrast, the mortality rates from cardiovascular diseases and all other causes were not increased. Four of the five living workers have pulmonary asbestosis; three of them have recently diagnosed cancers, including two additional lung cancers. We conclude that the extremely high morbidity and mortality in these workers were caused by intense exposure to crocidolite asbestos fibers.
The Faucet Aerator — A Source of Pseudomonas Infection
Authors: David F. Cross, Alberto Benchimol, E. Grey Dimond
Journal: New England Journal of Medicine (1966)

VIGILANCE is required in preventing surgical wound infection due to organisms of the genus pseudomonas. Keown et al.1 reported 5 cases of pseudomonas septicemia that followed open-heart surgery and were attributed to "sterilization" of their oxygenator in contaminated benzalkonium. Pseudomonas bacteremia after cardiac catheterization was traced by Shickman and his associates2 to contaminated catheters. After the death of an infant with pseudomonas infection, Wilson and her co-workers3 cultured this organism from the nursery scrub sink and traced its source to the faucet aerator. This source of pseudomonas infection was confirmed by Kresky4 and is now mentioned in a standard textbook . . .
Triple negative (CD3–/CD4–/CD8–) adult T cell leukemia/lymphoma, histologically presenting as CD30 (Ki-1)-positive anaplastic large cell lymphoma with clonal Epstein–Barr virus genome
Authors: T Kumura, M Hino, T Yamane, K Ohta, T Nakao, K Wakasa, N Tatsumi
Journal: Leukemia (2001)
Abstract 3647: Characterization of the relationship between mature neutrophils and tumor associated granulocytic myeloid-derived suppressor cells
Authors: Je-In Youn, Michelle M. Collazo, Dmitry Gabrilovich
Journal: Cancer Research (2011)

Abstract Myeloid-derived suppressor cells (MDSC) is a group of cells with potent immune suppressive activity that accumulate in many pathologic conditions. In cancer, most of MDSC are represented by cells with granulocytic phenotype, CD11b+Ly6ClowLy6G+, and morphology and are thus called granulocytic MDSC (G-MDSC). This phenotype and morphology are also shared by mature neutrophils (Neu) in naive mice. The relationship, if any, between G-MDSC and Neu remains unclear. In this study, we compared tumor associated G-MDSC and mature Neu. G-MDSC were freshly isolated from spleen of tumor-bearing mice. Because there are no known specific markers that differentiate between Neu and G-MDSC in tumor being mice or Neu and immature myeloid cells in naïve mice; Neu were isolated from naive mice by mobilizing them to the peritoneum (pNeu). We found that in contrast to pNeu, a substantial proportion of G-MDSC express the M-CSF receptor, CD115, CXCR4 and the CD244 molecule, also known as 2B4. pNeu have high amounts of lysosomes, endosomes and proteasomes, which was validated using immunofluorescence microscopy to measure the expression of associated proteins, LAMP2, EEA1, PSMA5, respectively. G-MDSC had significantly lower expression of LAMP2, EEA1, PSMA5. Also, G-MDSC, compared to pNeu, had significantly lower phagocytic activity, as measured by the uptake of latex beads in vitro. On the other hand, G-MDSC, but not pNeu, suppressed T-cell IFN-γ production upon antigen-specific stimulation. Interestingly, pNeu had higher arginase activity and nitric oxide production than G-MDSC, while G-MDSC had a significantly higher increase in reactive oxygen species levels upon PMA stimulation in vitro. This may explain the differences in suppressive activity. G-MDSC survived 3 days in culture, in the presence of GM-CSF. Within 24 hours in culture with GM-CSF, they became phenotypically and functionally similar to pNeu, with increased phagocytic capacity and LAMP2 expression and decreased expression of CD115, CXCR4, and CD244. These data suggest that, in cancer, G-MDSC may represent pathologically activated precursors of neutrophils. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3647. doi:10.1158/1538-7445.AM2011-3647
MS-26 * EXTRA CRANIAL METASTASIS IN A CASE OF CEREBRAL MENINGIOMA: A RARE CASE REPORT
Authors: F. Syed, P. Lachi, P. Chakravarthy, S. Uppin, A. Syed, D. Nair, D. Joseph, M. Irrakula, S. Pamidighantam, K. Naidu
Journal: Neuro-Oncology (2014)

Thirty one year aged male presented in Apr 2010 with complaints of headache and seizures. MRI brain showed a well defined extra axial lesion situated on right side of the coronal suture extending posteriorly in the parasagittal region which is hypointense to isointense on T1 W, & T2 W showing heterogenously enhancement on contrast administration. He underwent right frontal paramedian pericoronal craniotomy and total excision of the lesion. Intra operatively a large highly vascular firm dural based lesion attached to right frontal cortex. Post operative histopathology was - Grade 1 Fibroblastic Meningioma. After one year he presented with complaints of headache, vomiting and weakness of left upperlimb and lower limb. CT Brain showed a well defined hyper intense lesion with central hypodensity with perilesional edemaand features suggestive of recurrence. Second surgery done was right fronto parietal craniotomy and total excision of lesion. Intra operatively large highly vascular firm to soft suckable tumor attached at junction of falx and sinus embedding into right frontal cortexfound and gross total excison of tumor done. Post operative histopathology was grade III Meningioma. Post operatively he received adjuvant radiation therapy to Brain by 3Dimensional conformal radiotherapy on Linear accelerator to a dose of 60Gy @ 2Gy per fraction. He tolerated radiotherapy well and was on regular follow-up. In November 2013, he presented with complaints of chest pain and cough. CT Chest - Multiple inhomogenously enhancing lesions, involving both lungs, largest measuring 5 x 4.8 cm. CT guided biopsy - lung: Morphology and IHC with Vimentin- positive, EMA - positive, P63 - focally positive, TTF - negative, Ki 67 - 7%, suggestive of multiple pulmonary metastases in a diagnosed case of anaplastic meningioma. Now patient on palliative chemotherapy with Vincristine, Adriamycin and cyclophosphamide and he is doing well.
SP0172 Glucocorticoids: Still a threat to bone?
Authors: J. Compston
Journal: Annals of the Rheumatic Diseases (2013)

Osteoporosis is a common complication of oral glucocorticoid therapy and is associated with significant morbidity. Glucocorticoid-induced osteoporosis is characterised by rapid bone loss and increased fracture risk during the first few months of therapy. The increase in fracture risk is dose-related and is most prominent in the spine. Although awareness of glucocorticoid-induced osteoporosis has increased in recent years, the condition remains under-treated. Recently there have been advances in fracture risk assessment and treatment in glucocorticoid-induced osteoporosis. The fracture risk algorithm FRAX® includes glucocorticoid use as a risk factor but does not take account of the dose, thus underestimating fracture risk in individuals taking higher doses. A modification to FRAX has recently been developed that provides an adjustment for the dose of glucocorticoids. A range of pharmacological interventions is now available for the management of glucocorticoid-induced osteoporosis, including oral and intravenous bisphosphonates and the anabolic agent, teriparatide. New recommendations incorporating these advances have recently been issued by the American College of Rheumatology and a joint working group from the International Osteoporosis Foundation and the European Calcified Tissue Society. <h3>Disclosure of Interest</h3> None Declared
Abscess Formation in Myocardial Infarction
Authors: C. G. Tedeschi, Thomas D. Stevenson, Herbert M. Levenson
Journal: New England Journal of Medicine (1950)

IN 1933, Cossio and Berconsky1 reported a case of coronary occlusion with myocardial infarction in which an abscess was found in the infarcted area at post-mortem examination. As far as we could ascertain, this is the only report in the medical literature of this unusual complication of myocardial infarction.The patient of Cossio and Berconsky was a sixty-four-year-old man who complained of the symptoms considered characteristic of myocardial infarction: severe precordial pain, weakness and a sense of impending death. The patient was hospitalized on the fourth day of illness and treated symptomatically. The signs of a bronchopneumonic process developed and . . .
Unpleasant Alcohol Effect in Diabetes Associated With 3243 bp Mitochondrial tRNALeu(UUR) Mutation
Authors: Yoshihiko Suzuki, Yoshihito Atsumi, Kazuhiro Hosokawa, Matsuo Taniyama, Takashi Kadowaki, Yoshitomo Oka, Yasushi Tanaka, Takayuki Asahina, Kempei Matsuoka
Journal: Diabetes Care (1995)
Scientists Find New Applications For Cancer Maps
Authors: L. F. Anderson
Journal: JNCI Journal of the National Cancer Institute (1993)

Scientists Find New Applications For Cancer Maps Get access Linda F. Anderson Linda F. Anderson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 14, 21 July 1993, Pages 1111–1112, https://doi.org/10.1093/jnci/85.14.1111 Published: 21 July 1993
Out of Africa — Caring for Patients with Ebola
Authors: Eric J. Rubin, Lindsey R. Baden
Journal: New England Journal of Medicine (2014)

Although the Ebola virus was recognized in 1976,1 until now Ebola virus disease (EVD) had been confined to remote areas in Africa, occurring in discrete outbreaks. Even with the thousands of cases in the current outbreak, most cases occur in areas where tragically few resources are available to care for affected patients — in Guinea, Liberia, and Sierra Leone. However, a small number of patients have been transferred to hospitals with modern technology. In addition, in-country transmission has led to new cases of Ebola in Nigeria, Spain, and the United States. This is a troubling development, but it affords us . . .
Bevacizumab in patients with advanced platinum-resistant ovarian cancer
Authors: S. A. Cannistra, U. Matulonis, R. Penson, R. Wenham, D. Armstrong, R. A. Burger, H. Mackey, J. Douglas, J. Hambleton, W. McGuire
Journal: Journal of Clinical Oncology (2006)

5006 Background: Bevacizumab (BV), a recombinant, humanized monoclonal antibody directed against vascular endothelial growth factor, has demonstrated clinical benefit in multiple tumor types. Activity in ovarian cancer (OC) has been reported in phase II studies in patients (pts) with recurrent disease. We now describe the activity/safety of BV in pts with platinum-resistant OC (PROC) that progressed after topotecan or liposomal doxorubicin (LD). Methods: Eligibility criteria for this multicenter, Phase II study included primary or secondary PROC that progressed within 3 months of topotecan or LD, 3 or fewer prior chemotherapy regimens, and a performance status (PS) 0 or 1. BV was dosed at 15 mg/kg q 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) as defined by RECIST. A two-stage design was utilized with H 1 set at 15%. Secondary endpoints included progression-free survival (PFS), duration of response, overall survival (OS), and safety. Results: The study enrolled 44 of the intended 53 pts, closing early due to a higher than expected rate of gastrointestinal perforations (GIP). Baseline characteristics included median age 60 yrs (range 31–87); PS 0 in 26 pts, 1 in 18 pts; 2 prior chemotherapy regimens in 20 pts, 3 in 24 pts. Preliminary efficacy: ORR (CR+PR), 7/44 (16%). Median duration of response was 12 weeks, with 2 pts continuing on study &gt;5 months. Serious adverse events (SAEs) were reported in 18/44 pts (41%). Selected SAEs included GIP 5 (11%; one occurred more than 30 days after coming off study while on paclitaxel and commercial Avastin®), bowel obstruction 5 (11%), arterial thromboembolic events 4 (9%), delayed wound healing 2 (5%), and one case each of pulmonary hypertension, hypertensive encephalopathy, and hypoxia. Conclusions: BV has single agent activity in women with PROC, but is associated with substantial toxicity in this population. Trials are ongoing in less heavily treated, newly diagnosed pts with OC to evaluate the efficacy and safety of BV in these disease settings. Identification of risk factors for BV-associated adverse events requires further study. [Table: see text]
Clinical and Pathological Features of Bacillary Peliosis Hepatis in Association with Human Immunodeficiency Virus Infection
Authors: Luke A. Perkocha, Sharon M. Geaghan, T.S. Benedict Yen, Steven L. Nishimura, Steven P. Chan, Richard Garcia-Kennedy, Gordon Honda, Amy C. Stoloff, Harvey Z. Klein, Ronald L. Goldman, Sharon Van Meter, Linda D. Ferrell, Philip E. LeBoit
Journal: New England Journal of Medicine (1990)

Peliosis hepatis is characterized by cystic, blood-filled spaces in the liver and is seen in patients with chronic infections or advanced cancer and as a consequence of therapy with anabolic steroids. Cutaneous bacillary angiomatosis is a bacterial infection that occurs in patients with human immunodeficiency virus (HIV) infection; its histologic appearance is that of a pseudoneoplastic vascular proliferation.
FRI0330 Development of cut-off values for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score (JADAS):
Authors: A. Consolaro, G. Bracciolini, A. Frisina, N. Ruperto, S. Magni-Manzoni, C. Malattia, S. Pederzoli, N. Solari, S. Davì, A. Martini, A. Ravelli
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In the last decade, there have been major advances in the management of juvenile idiopathic arthritis (JIA). A reliable documentation of these progresses creates the need for validated criteria that describe precisely patient states. We recently, developed the cut-off values for remission, minimal disease activity and acceptable symptom states in JIA based on the JADAS (1). <h3>Objectives</h3> To determine the JADAS cut-offs for high disease activity (HDA) in JIA. <h3>Methods</h3> For the selection of cut-offs, data from a clinical database including 618 children with JIA were used. Patients were defined as having HDA when the physician made one of the following therapeutic interventions: 1) start of methotrexate (MTX); 2) intra-articular corticosteroid injection; 3) start of a biologic medication; 4) start of systemic corticosteroids. Patients were defined as having low disease activity (LDA) when they were receiving no therapy or had therapy discontinued, tapered or left unchanged for &gt;1 year. For each patient, 1 visit in HDA and 1 visit in LDA was retained for the analyses. "Optimal" JADAS cut-offs were determined by calculating the 25th percentile of cumulative score distribution in patients with HDA and by assessing their ability to discriminate between HDA and LDA through ROC curve analysis (including calculation of Youden index and fixed 90% specificity). Cross-validation of cut-offs was performed in 490 JIA patients enrolled in the PRINTO MTX trial (2) and was based on assessment of discriminant validity. <h3>Results</h3> The cut-offs were calculated separately for patients with oligoarticular and polyarticular course of joint disease (irrespective of ILAR category) owing to the different severity of these 2 JIA phenotypes. The table shows the cut-offs for HDA for JADAS-71 version, defined according to the different statistical methods. The cut-offs that showed the best trade-off between sensitivity and specificity were selected for cross-validation analyses. These analyses showed that at baseline visit of MTX trial 94.7% of patients had a JADAS-71 higher than the HDA cut-off for polyarthritis. At 6-month visit, the percentage of patients with a JADAS-71 higher than the cut-off was 85.6% among nonresponders and 23.8% among responders. <h3>Conclusions</h3> We developed the JADAS cut-offs for HDA in JIA. The cut-offs revealed strong discriminant ability in a clinical trial and are, therefore, potentially applicable in clinical practice, observational investigations, and therapeutic studies. <h3>References</h3> Consolaro A et al. A&amp;R, in press. Ruperto et al. A&amp;R 2004;50:2191-201 <h3>Disclosure of Interest</h3> None Declared